Last reviewed · How we verify
A/B
A/B is a transdermal delivery system designed to provide controlled release of an active pharmaceutical ingredient through the skin.
At a glance
| Generic name | A/B |
|---|---|
| Also known as | Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, Bupivacaine 2%, VersaPro cream |
| Sponsor | Transdermal Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a platform technology rather than a specific drug entity. Transdermal Therapeutics, Inc. developed A/B as a transdermal patch formulation to enable systemic drug delivery via percutaneous absorption, potentially improving bioavailability, reducing dosing frequency, and enhancing patient compliance compared to oral or injectable routes.
Approved indications
Common side effects
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Evaluation of Novel Spectacles Intended for Myopia Management in a Short-Term Study (NA)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |